News and Trends 18 Nov 2022
MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma
KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made…